Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Inclusion Criteria:

- Participant must be 18 years of age inclusive or older

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

- Participants with relapsed or refractory MM who have received at least 3 prior lines
of therapy for MM, including PIs and IMiDs or at least 2 prior lines if at least one
of these lines consisted of 2 or more multiagent regimens (eg, Induction regimen with
autologous stem cell transplant followed by maintenance).

- RRMM with measurable disease:

- Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or

- Urine M protein ≥200 mg/24 hours measured using urine protein
immunoelectrophoresis and/or

- Serum free light chain (sFLC) MM without measurable M protein in serum or urine
per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig
kappa lambda free light chain ratio <0.26 or >1.65).

- Men or woman or childbearing potential should agree to use contraception.

- Substudy 01, 02 (Terminated), 03 (Terminated): Anti-CD38 therapy naïve or prior
exposure to such drugs without being refractory but with a wash out of at least 6
months after the last dose. "Refractory" is defined as progressing within 60 days of
last dose of anti-CD38 targeting therapy.

- Substudy 04: Participants must be exposed to anti-CD38 and anti-BCMA therapy

Exclusion Criteria:

- Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal
gammopathy of undetermined significance, or smoldering myeloma.

- Uncontrolled infection within 14 days prior to first study intervention
administration.

- Clinically significant cardiac (including valvular) or vascular disease within 3
months prior to first study intervention administration, eg, myocardial infarction,
unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary
intervention) or peripheral artery revascularization, left ventricular ejection
fraction <40%, heart failure New York Heart Association Classes III and IV, stroke,
transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac
arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0).

- Known acquired immunodeficiency syndrome-related illness or known human
immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis
A.

- Uncontrolled or active hepatitis B virus (HBV) infection.

- Active hepatitis C virus (HCV) infection.

- Any of the following within 3 months prior to first study intervention administration:
treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious
or inflammatory bowel disease.

- Second malignancy other than basal cell or squamous cell carcinoma of the skin or in
situ carcinoma, unless they are successfully treated with curative intent for more
than 3 years before first study intervention administration.

- Any anti-MM drug treatment within 14 days before first study intervention
administration, including dexamethasone.

- Participants with a contraindication to treatment.

- Vaccination with a live vaccine 4 weeks before the start of the study.

- Hemoglobin <8 g/dL.

- Platelets <50 x 10^9/L.

- Absolute neutrophil count <1.5 x 10^9/L.

- Creatinine clearance <30 mL/min.

- Total bilirubin >1.5 x ULN, except for known Gilbert syndrome in which direct
bilirubin should be ≤2.5 x ULN.

- Aspartate aminotransferase and/or alanine aminotransferase >3 x ULN.

- Patients with grade 3 or 4 hypercalcemia.

- Substudy 01:

- Malabsorption syndrome or any condition that can significantly impact the
absorption of pomalidomide.

- For the first 10 participants: Body weight ≤70 kg

- Substudy 02 (terminated):

- History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or
carcinoma in situ of the cervix, or other local tumors, even if considered cured
by local treatment.

- Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to
the first dose of SAR439459.

- Prothrombin time or INR >1.5 × upper limit of normal (ULN).

- Substudy 03 (terminated):

- Current corneal epithelial disease except mild punctate keratopathy

- Patients who have received prior therapy with belantamab mafodotin

- Substudy 04:

- Central nervous system or leptomeningeal disease.

- Medical history of seizure.

- Participants currently receiving hepatically metabolized narrow therapeutic index
drugs (eg, digoxin, warfarin) if cannot be closely monitored.

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.